Skip to main content

Testosterone Replacement Therapy in Men: Effects on Fertility and Health

  • Chapter
  • First Online:
Biennial Review of Infertility

Abstract

Epidemiological studies clearly demonstrated a gradual decline in serum testosterone levels as men age, resulting in a cluster of clinical presentations such as decrease in energy, libido, sexual function, bone mineral density, muscle mass, and mood. This condition, termed late-onset hypogonadism (LOH) but also known as testosterone deficiency syndrome, partial androgen deficiency in aging men, or “andropause” in laymen’s term, can be managed by testosterone replacement therapy (TRT). In addition to improvement in many signs and symptoms of LOH, a wealth of current literature suggests that TRT may also have other health benefits such as increase in muscle mass, reduction in fat mass, improvement in glucose metabolic and lipid profiles, and voiding function. Furthermore, latest observational and interventional studies demonstrated that the risks of severe adverse events with TRT such as cardiovascular events and prostate cancer are much lower than previously expected. Among the various side effects of TRT, suppression of spermatogenesis leading to infertility is not frequently addressed, partly because most men who develop LOH requiring TRT are presumably past the traditional reproductive age. However, as seen in most societies, men have been postponing paternity until later age when they are at risk to have LOH. The impact of TRT on male reproductive health is thus a relevant and timely health issue. Clinicians managing men’s health should be aware of the potential health risks, in addition to the efficacy, of TRT when counseling men presenting with LOH.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gooren LJ, Behre HM. Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. Aging Male. 2012;15(1):22–7.

    Article  PubMed  Google Scholar 

  2. Ramasamy R, Fisher ES, Schlegel PN. Testosterone replacement and prostate cancer. Indian J Urol. 2012;28(2):123–8.

    Article  PubMed  Google Scholar 

  3. Seftel A. Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis. Int J Impot Res. 2006;18(3):223–8. Review.

    Article  PubMed  CAS  Google Scholar 

  4. Bianco SD, Kaiser UB. The genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat Rev Endocrinol. 2009;5(10):569–76.

    Article  PubMed  CAS  Google Scholar 

  5. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589–98.

    Article  PubMed  CAS  Google Scholar 

  6. Rohrmann S, Platz EA, Selvin E, Shiels MS, Joshu CE, Menke A, et al. The prevalence of low sex steroid hormone concentrations in men in the Third National Health and Nutrition Examination Survey (NHANES III). Clin Endocrinol (Oxf). 2011;75(2):232–9.

    Article  Google Scholar 

  7. Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89(12):5920–6.

    Article  PubMed  CAS  Google Scholar 

  8. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–9.

    Article  PubMed  CAS  Google Scholar 

  9. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26(6):833–76.

    Article  PubMed  CAS  Google Scholar 

  10. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295(11):1288–99.

    Article  PubMed  CAS  Google Scholar 

  11. Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2007;30(2):234–8.

    Article  PubMed  CAS  Google Scholar 

  12. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000;23(4):490–4.

    Article  PubMed  CAS  Google Scholar 

  13. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036–41.

    Article  PubMed  CAS  Google Scholar 

  14. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166(15):1660–5.

    Article  PubMed  CAS  Google Scholar 

  15. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116(23):2694–701.

    Article  PubMed  CAS  Google Scholar 

  16. Moskovic DJ, Araujo AB, Lipshultz LI, Khera M. The 20-year public health impact and direct cost of testosterone deficiency in U.S. men. J Sex Med. 2013;10:562–9.

    Article  PubMed  Google Scholar 

  17. Brown-Sequard CE. The effects produced on man by subcutaneous injection of a liquid obtained from the testicles of animals. Lancet. 1889;137:105–7.

    Article  Google Scholar 

  18. Cunningham GR, Toma SM. Clinical review: why is androgen replacement in males controversial? J Clin Endocrinol Metab. 2011;96(1):38–52.

    Article  PubMed  CAS  Google Scholar 

  19. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59.

    Article  PubMed  CAS  Google Scholar 

  20. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res. 2009;21(1):1–8.

    Article  PubMed  Google Scholar 

  21. Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Male Reproduction and Urology. Androgen deficiency in the aging male. Fertil Steril. 2008;90(5 Suppl):S83–7.

    Google Scholar 

  22. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(8):2647–53.

    Article  PubMed  CAS  Google Scholar 

  23. Srinivas-Shankar U, Roberts SA, Connolly MJ, O’Connell MD, Adams JE, Oldham JA, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639–50.

    Article  PubMed  CAS  Google Scholar 

  24. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010;58(6):1134–43.

    Article  PubMed  Google Scholar 

  25. Casaburi R, Bhasin S, Cosentino L, Porszasz J, Somfay A, Lewis MI, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(8):870–8.

    Article  PubMed  Google Scholar 

  26. Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid ­treatment. J Clin Endocrinol Metab. 2003;88(7):3167–76.

    Article  PubMed  CAS  Google Scholar 

  27. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22.

    Article  PubMed  CAS  Google Scholar 

  28. Bakhshi V, Elliott M, Gentili A, Godschalk M, Mulligan T. Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc. 2000;48(5):550–3.

    PubMed  CAS  Google Scholar 

  29. Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2011;66(10):1090–9.

    Article  PubMed  CAS  Google Scholar 

  30. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a ­randomized controlled trial. JAMA. 2008;299(1):39–52.

    Article  PubMed  CAS  Google Scholar 

  31. Stĕpán JJ, Lachman M, Zvĕrina J, Pacovský V, Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab. 1989;69(3):523–7.

    Article  PubMed  Google Scholar 

  32. Benito M, Gomberg B, Wehrli FW, Weening RH, Zemel B, Wright AC, et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab. 2003;88(4):1497–502.

    Article  PubMed  CAS  Google Scholar 

  33. Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM, Rockwood AL, et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168(1):47–54.

    Article  PubMed  CAS  Google Scholar 

  34. LeBlanc ES, Nielson CM, Marshall LM, Lapidus JA, Barrett-Connor E, Ensrud KE, et al. The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab. 2009;94(9):3337–46.

    Article  PubMed  CAS  Google Scholar 

  35. Abbasi AA, Rudman D, Wilson CR, Drinka PJ, Basu SN, Mattson DE, et al. Observations on nursing home residents with a history of hip fracture. Am J Med Sci. 1995;310(6):229–34.

    PubMed  CAS  Google Scholar 

  36. Jackson JA, Riggs MW, Spiekerman AM. Testosterone deficiency as a risk factor for hip fractures in men: a case-control study. Am J Med Sci. 1992;304(1):4–8.

    Article  PubMed  CAS  Google Scholar 

  37. Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc. 1991;39(8):766–71.

    PubMed  CAS  Google Scholar 

  38. Francis RM. Androgen replacement in aging men. Calcif Tissue Int. 2001;69(4):235–8.

    Article  PubMed  CAS  Google Scholar 

  39. Aversa A, Bruzziches R, Francomano D, Greco EA, Fornari R, Di Luigi L, et al. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male. 2012;15(2):96–102.

    Article  PubMed  CAS  Google Scholar 

  40. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085–98.

    Article  PubMed  CAS  Google Scholar 

  41. Benito M, Vasilic B, Wehrli FW, Bunker B, Wald M, Gomberg B, et al. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J Bone Miner Res. 2005;20(10):1785–91.

    Article  PubMed  CAS  Google Scholar 

  42. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280–93.

    Article  CAS  Google Scholar 

  43. Tracz MJ, Sideras K, Boloña ER, Haddad RM, Kennedy CC, Uraga MV, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;91(6):2011–6.

    Article  PubMed  CAS  Google Scholar 

  44. Travison TG, Araujo AB, Kupelian V, O’Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab. 2007;92(2):549–55.

    Article  PubMed  CAS  Google Scholar 

  45. Rhoden EL, Telöken C, Sogari PR, Souto CA. The relationship of serum testosterone to erectile function in normal aging men. J Urol. 2002;167(4):1745–8.

    Article  PubMed  CAS  Google Scholar 

  46. Marberger M, Wilson TH, Rittmaster RS. Low serum testosterone levels are poor predictors of sexual dysfunction. BJU Int. 2011;108(2):256–62.

    Article  PubMed  Google Scholar 

  47. Kupelian V, Shabsigh R, Travison TG, Page ST, Araujo AB, McKinlay JB. Is there a relationship between sex hormones and erectile dysfunction? Results from the Massachusetts Male Aging Study. J Urol. 2006;176(6 Pt 1):2584–8.

    Article  PubMed  CAS  Google Scholar 

  48. Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35.

    Article  PubMed  CAS  Google Scholar 

  49. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol. 2000;164(2):371–5.

    Article  PubMed  CAS  Google Scholar 

  50. Boloña ER, Uraga MV, Haddad RM, Tracz MJ, Sideras K, Kennedy CC, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):20–8.

    PubMed  Google Scholar 

  51. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63(4):381–94.

    Article  CAS  Google Scholar 

  52. Rosenthal BD, May NR, Metro MJ, et al. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology. 2006;67:571–4.

    Article  PubMed  Google Scholar 

  53. Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men non-responders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8:284–93.

    Article  PubMed  CAS  Google Scholar 

  54. Shamloul R, Ghanem H, Fahmy I, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med. 2005;2:559–64.

    Article  PubMed  CAS  Google Scholar 

  55. Hwang TI, Chen HE, Tsai TF, et al. Combined use of androgen and sildenafil for hypogonadal patients non responsive to sildenafil alone. Int J Impot Res. 2006;18:400–4.

    Article  PubMed  CAS  Google Scholar 

  56. Shabsigh R, Kaufman JM, Steidle C, et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:658–63.

    Article  PubMed  CAS  Google Scholar 

  57. Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1999;84(2):573–7.

    Article  PubMed  CAS  Google Scholar 

  58. Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;62(2):188–93.

    Article  PubMed  CAS  Google Scholar 

  59. Gouras GK, Xu H, Gross RS, Greenfield JP, Hai B, Wang R, et al. Testosterone reduces neuronal secretion of Alzheimer’s beta-amyloid peptides. Proc Natl Acad Sci USA. 2000;97(3):1202–5.

    Article  PubMed  CAS  Google Scholar 

  60. Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract. 2009;15(4):289–305.

    Article  PubMed  Google Scholar 

  61. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839–53.

    Article  PubMed  CAS  Google Scholar 

  62. Pope Jr HG, Amiaz R, Brennan BP, Orr G, Weiser M, Kelly JF, et al. Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to ­standard antidepressant treatment. J Clin Psychopharmacol. 2010;30(2):126–34.

    Article  PubMed  CAS  Google Scholar 

  63. Behre HM, Tammela TL, Arver S, Tolrá JR, Bonifacio V, Lamche M, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male. 2012;15(4):198–207.

    Article  PubMed  CAS  Google Scholar 

  64. Zhang XW, Liu ZH, Hu XW, Yuan YQ, Bai WJ, Wang XF, et al. Androgen replacement therapy improves psychological distress and health-related quality of life in late onset hypogonadism patients in Chinese population. Chin Med J (Engl). 2012;125(21):3806–10.

    CAS  Google Scholar 

  65. Ho CC, Tong SF, Low WY, Ng CJ, Khoo EM, Lee VK, et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int. 2012;110(2):260–5.

    Article  PubMed  CAS  Google Scholar 

  66. Tong SF, Ng CJ, Lee BC, Lee VK, Khoo EM, Lee EG, et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian J Androl. 2012;14(4):604–11.

    Article  PubMed  CAS  Google Scholar 

  67. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome–a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469–80.

    Article  PubMed  CAS  Google Scholar 

  68. Corona G, Rastrelli G, Morelli A, Vignozzi L, Mannucci E, Maggi M. Hypogonadism and metabolic syndrome. J Endocrinol Invest. 2011;34(7):557–67.

    PubMed  CAS  Google Scholar 

  69. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):272–83.

    Article  PubMed  CAS  Google Scholar 

  70. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med. 2001;111(4):261–9.

    Article  PubMed  CAS  Google Scholar 

  71. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34(6 Pt 1):528–40.

    Article  PubMed  CAS  Google Scholar 

  72. Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57(1):80–8.

    Article  PubMed  CAS  Google Scholar 

  73. Cherrier MM, Plymate S, Mohan S, Asthana S, Matsumoto AM, Bremner W, et al. Relationship between testosterone supplementation and insulin-like growth factor-I levels and cognition in healthy older men. Psychoneuroendocrinology. 2004;29(1):65–82.

    Article  PubMed  CAS  Google Scholar 

  74. Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005;64(12):2063–8.

    Article  PubMed  CAS  Google Scholar 

  75. Haren MT, Wittert GA, Chapman IM, Coates P, Morley JE. Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas. 2005;50(2):124–33.

    Article  PubMed  CAS  Google Scholar 

  76. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab. 2011;25(2):337–53.

    Article  PubMed  CAS  Google Scholar 

  77. Corona G, Monami M, Boddi V, Cameron-Smith M, Fisher AD, de Vita G, et al. Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med. 2010;7(4 Pt 1):1557–64.

    Article  PubMed  CAS  Google Scholar 

  78. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165(5):687–701. doi:10.1530/EJE-11-0447.

    Article  PubMed  CAS  Google Scholar 

  79. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96(22):1821–5.

    Article  PubMed  CAS  Google Scholar 

  80. Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab. 2010;21(8):496–503.

    Article  PubMed  CAS  Google Scholar 

  81. Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med. 2011;8(3):639–54.

    Article  PubMed  CAS  Google Scholar 

  82. Saad F. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev. 2012;28 Suppl 2:52–9.

    Article  PubMed  Google Scholar 

  83. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75.

    Article  PubMed  CAS  Google Scholar 

  84. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29–39.

    PubMed  CAS  Google Scholar 

  85. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451–7.

    Article  PubMed  Google Scholar 

  86. Morris PD, Channer KS. Testosterone and cardiovascular disease in men. Asian J Androl. 2012;14(3):428–35.

    Article  PubMed  CAS  Google Scholar 

  87. Saad F, Aversa A, Isidori AM, Zafalon L, Zitzmann M, Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–85.

    Article  PubMed  CAS  Google Scholar 

  88. Morgentaler A. Words of wisdom. Re: adverse events associated with testosterone administration. Eur Urol. 2011;59(3):465.

    Article  PubMed  Google Scholar 

  89. Favilla V, Cimino S, Castelli T, Madonia M, Barbagallo I, Morgia G. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int. 2010;106(11):1700–3.

    Article  PubMed  Google Scholar 

  90. Litman HJ, Bhasin S, O’Leary MP, Link CL, McKinlay JB, BACH Survey Investigators. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int. 2007;100(2):321–6.

    Article  PubMed  CAS  Google Scholar 

  91. Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, et al. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology. 2007;69(4):708–13.

    Article  PubMed  Google Scholar 

  92. Liao CH, Chiang HS, Yu HJ. Serum testosterone levels significantly correlate with nocturia in men aged 40-79 years. Urology. 2011;78(3):631–5.

    Article  PubMed  Google Scholar 

  93. Polackwich AS, Ostrowski KA, Hedges JC. Testosterone replacement therapy and prostate health. Curr Urol Rep. 2012;13(6):441–6.

    Article  PubMed  Google Scholar 

  94. Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, Barrett-Connor E. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int. 2010;105(11):1554–9.

    Article  PubMed  CAS  Google Scholar 

  95. Shigehara K, Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol. 2011;52(10):657–63.

    Article  PubMed  Google Scholar 

  96. Takao T, Tsujimura A, Okuda H, Yamamoto K, Fukuhara S, Matsuoka Y, et al. Lower urinary tract symptoms and erectile dysfunction associated with depression among Japanese patients with late-onset hypogonadism symptoms. Aging Male. 2011;14(2):110–4.

    Article  PubMed  Google Scholar 

  97. Haider A, Gooren LJ, Padungtod P, Saad F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia. 2009;41(1):7–13.

    Article  PubMed  CAS  Google Scholar 

  98. Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl. 2002;25(2):119–25.

    Article  PubMed  CAS  Google Scholar 

  99. Karazindiyanoğlu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male. 2008;11(3):146–9.

    Article  PubMed  CAS  Google Scholar 

  100. Kalinchenko S, Vishnevskiy EL, Koval AN, Mskhalaya GJ, Saad F. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male. 2008;11(2):57–61.

    Article  PubMed  CAS  Google Scholar 

  101. Amano T, Imao T, Takemae K, Iwamoto T, Nakanome M. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male. 2010;13(4):242–6.

    Article  PubMed  CAS  Google Scholar 

  102. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male. 2011;14(1):53–8.

    Article  PubMed  Google Scholar 

  103. Huggins C, Steven RE, Hodges CV. Studies on prostatic cancer. Arch Surg. 1941;43:209–23.

    Article  CAS  Google Scholar 

  104. Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am. 2007;34(4):555–63.

    Article  PubMed  Google Scholar 

  105. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–61.

    Article  PubMed  CAS  Google Scholar 

  106. Raynaud JP, Gardette J, Rollet J, Legros JJ. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. BJU Int. 2013.

  107. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920–2.

    Article  PubMed  CAS  Google Scholar 

  108. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173(2):533–6.

    Article  PubMed  CAS  Google Scholar 

  109. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6(4):1165–70.

    Article  PubMed  CAS  Google Scholar 

  110. Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int. 2009;103(1):62–4.

    Article  PubMed  CAS  Google Scholar 

  111. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25(1):24–8.

    Article  PubMed  CAS  Google Scholar 

  112. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109(3):536–41.

    Article  PubMed  CAS  Google Scholar 

  113. Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 2013;189(1 Suppl):S26–33.

    Article  PubMed  CAS  Google Scholar 

  114. Braunstein GD. Clinical practice. Gynecomastia. N Engl J Med. 2007;357(12):1229–37.

    Article  PubMed  CAS  Google Scholar 

  115. Hanafy HM. Testosterone therapy and obstructive sleep apnea: is there a real connection? J Sex Med. 2007;4(5):1241–6.

    Article  PubMed  CAS  Google Scholar 

  116. Basaria S, Dobs AS. Hypogonadism and androgen replacement therapy in elderly men. Am J Med. 2001;110(7):563–72.

    Article  PubMed  CAS  Google Scholar 

  117. Thomas SR, Evans PJ, Holland PA, Biswas M. Invasive breast cancer after initiation of testosterone replacement therapy in a man–a warning to endocrinologists. Endocr Pract. 2008;14(2):201–3.

    Article  PubMed  Google Scholar 

  118. Heckel M. Production of oligospermia in a man by the use of testosterone propionate. Proc Soc Exp Biol Med. 1939;40:658–9.

    Google Scholar 

  119. Ruwanpura SM, McLachlan RI, Meachem SJ. Hormonal regulation of male germ cell development. J Endocrinol. 2010;205(2):117–31.

    Article  PubMed  CAS  Google Scholar 

  120. Walker WH. Testosterone signaling and the regulation of spermatogenesis. Spermatogenesis. 2011;1(2):116–20.

    Article  PubMed  Google Scholar 

  121. Heckel NJ, Rosso WA, Kestel L. Spermatogenic rebound phenomenon after administration of testosterone propionate. J Clin Endocrinol Metab. 1951;11(3):235–45.

    Article  PubMed  Google Scholar 

  122. Nieschlag E, Vorona E, Wenk M, Hemker AK, Kamischke A, Zitzmann M. Hormonal male contraception in men with normal and subnormal semen parameters. Int J Androl. 2011;34(6 Pt 1):556–67.

    Article  PubMed  CAS  Google Scholar 

  123. Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Kirmeyer S, Mathews TJ, et al. Births: final data for 2009. Natl Vital Stat Rep. 2011;60(1):1–70.

    PubMed  Google Scholar 

  124. Nieschlag E. Clinical trials in male hormonal contraception. Contraception. 2010;82(5):457–70.

    Article  PubMed  CAS  Google Scholar 

  125. World Health Organization. Contraceptive efficacy of testosterone-induced azoospermia in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Lancet. 1990;336(8721):955–9.

    Article  Google Scholar 

  126. World Health Organization. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65(4):821–9.

    Google Scholar 

  127. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab. 1995;80(8):2394–403.

    Article  PubMed  CAS  Google Scholar 

  128. Nieschlag E, Hoogen H, Bölk M, Schuster H, Wickings EJ. Clinical trial with testosterone undecanoate for male fertility control. Contraception. 1978;18(6):607–14.

    Article  PubMed  CAS  Google Scholar 

  129. Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. J Clin Endocrinol Metab. 1999;84(10):3642–7.

    Article  PubMed  CAS  Google Scholar 

  130. Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab. 2003;88(2):562–8.

    Article  PubMed  CAS  Google Scholar 

  131. Gu Y, Liang X, Wu W, Liu M, Song S, Cheng L, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab. 2009;94(6):1910–5.

    Article  PubMed  CAS  Google Scholar 

  132. Liu PY, Swerdloff RS, Anawalt BD, Anderson RA, Bremner WJ, Elliesen J, et al. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab. 2008;93(5):1774–83.

    Article  PubMed  CAS  Google Scholar 

  133. Ilani N, Liu PY, Swerdloff RS, Wang C. Does ethnicity matter in male hormonal contraceptive efficacy? Asian J Androl. 2011;13(4):579–84.

    Article  PubMed  Google Scholar 

  134. Johnson L, Barnard JJ, Rodriguez L, Smith EC, Swerdloff RS, Wang XH, et al. Ethnic differences in testicular structure and spermatogenic potential may predispose testes of Asian men to a heightened sensitivity to steroidal contraceptives. J Androl. 1998;19(3):348–57.

    PubMed  CAS  Google Scholar 

  135. Hikim AP, Wang C, Lue Y, Johnson L, Wang XH, Swerdloff RS. Spontaneous germ cell apoptosis in humans: evidence for ethnic differences in the susceptibility of germ cells to programmed cell death. J Clin Endocrinol Metab. 1998;83(1):152–6.

    Article  PubMed  CAS  Google Scholar 

  136. Santner SJ, Albertson B, Zhang GY, Zhang GH, Santulli M, et al. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab. 1998;83:2104–9.

    Article  PubMed  CAS  Google Scholar 

  137. Wang C, Catlin DH, Starcevic B, Leung A, DiStefano E, et al. Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: influence of ethnicity and age. J Clin Endocrinol Metab. 2004;89:2936–41.

    Article  PubMed  CAS  Google Scholar 

  138. Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, et al. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab. 1991;72:1242–8.

    Article  PubMed  CAS  Google Scholar 

  139. Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995;4:735–41.

    PubMed  CAS  Google Scholar 

  140. Ross RK, Bernstein L, Lobo RA, Shimizu H, Stanczyk FZ, et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339:887–9.

    Article  PubMed  CAS  Google Scholar 

  141. Orwoll ES, Nielson CM, Labrie F, Barrett-Connor E, Cauley JA, et al. Evidence for geographical and racial variation in serum sex steroid levels in older men. J Clin Endocrinol Metab. 2010;95:E151–60.

    Article  PubMed  CAS  Google Scholar 

  142. Schulze JJ, Lundmark J, Garle M, Skilving I, Ekstrom L, et al. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation. J Clin Endocrinol Metab. 2008;93:2500–6.

    Article  PubMed  CAS  Google Scholar 

  143. Swanson C, Mellstrom D, Lorentzon M, Vandenput L, Jakobsson J, et al. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J Clin Endocrinol Metab. 2007;92:4878–82.

    Article  PubMed  CAS  Google Scholar 

  144. Jakobsson J, Ekstrom L, Inotsume N, Garle M, Lorentzon M, et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab. 2006;91:687–93.

    Article  PubMed  CAS  Google Scholar 

  145. Vandenput L, Labrie F, Mellstrom D, Swanson C, Knutsson T, et al. Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men. J Bone Miner Res. 2007;22:220–7.

    Article  PubMed  CAS  Google Scholar 

  146. Xue Y, Sun D, Daly A, Yang F, Zhou X, et al. Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet. 2008;83:337–46.

    Article  PubMed  CAS  Google Scholar 

  147. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer [published erratum appears in Proc Natl Acad Sci USA 1997;94(15):8272]. Proc Natl Acad Sci USA. 1997;94:3320–3.

    Article  PubMed  CAS  Google Scholar 

  148. Esteban E, Rodon N, Via M, Gonzalez-Perez E, Santamaria J, et al. Androgen receptor CAG and GGC polymorphisms in Mediterraneans: repeat dynamics and population relationships. J Hum Genet. 2006;51:129–36.

    Article  PubMed  CAS  Google Scholar 

  149. Eckardstein SV, Schmidt A, Kamischke A, Simoni M, Gromoll J, et al. CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol (Oxf). 2002;57:647–55.

    Article  CAS  Google Scholar 

  150. Li JW, Gu YQ. Predictors for partial suppression of spermatogenesis of hormonal male contraception. Asian J Androl. 2008;10:723–30.

    Article  PubMed  CAS  Google Scholar 

  151. Wang C, Berman NG, Veldhuis JD, Der T, McDonald V, et al. Graded testosterone infusions distinguish gonadotropin negative-feedback responsiveness in Asian and white men—a Clinical Research Center study. J Clin Endocrinol Metab. 1998;83:870–6.

    Article  PubMed  CAS  Google Scholar 

  152. Kamischke A, Plöger D, Venherm S, von Eckardstein S, von Eckardstein A, Nieschlag E. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. Clin Endocrinol (Oxf). 2000;53(1):43–52.

    Article  CAS  Google Scholar 

  153. Qoubaitary A, Meriggiola C, Ng CM, Lumbreras L, Cerpolini S, Pelusi G, et al. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J Androl. 2006;27(6):853–67.

    Article  PubMed  CAS  Google Scholar 

  154. McLachlan RI, McDonald J, Rushford D, Robertson DM, Garrett C, Baker HW. Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception. Contraception. 2000;62(2):73–8.

    Article  PubMed  CAS  Google Scholar 

  155. Knuth UA, Behre H, Belkien L, Bents H, Nieschlag E. Clinical trial of 19-nortestosterone-hexoxyphenylpropionate (Anadur) for male fertility regulation. Fertil Steril. 1985;44(6):814–21.

    PubMed  CAS  Google Scholar 

  156. Sundaram K, Kumar N, Bardin CW. 7 alpha-Methyl-19-nortestosterone: an ideal androgen for replacement therapy. Recent Prog Horm Res. 1994;49:373–6.

    PubMed  CAS  Google Scholar 

  157. von Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F, et al. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab. 2003;88(11):5232–9.

    Article  CAS  Google Scholar 

  158. Bonetti A, Tirelli F, Catapano A, Dazzi D, Dei Cas A, Solito F, et al. Side effects of anabolic androgenic steroids abuse. Int J Sports Med. 1996;17(4):259–62.

    Article  PubMed  CAS  Google Scholar 

  159. Knuth UA, Maniera H, Nieschlag E. Anabolic steroids and semen parameters in bodybuilders. Fertil Steril. 1989;52(6):1041–7.

    PubMed  CAS  Google Scholar 

  160. Schürmeyer T, Knuth UA, Belkien L, Nieschlag E. Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. Lancet. 1984;1(8374):417–20.

    Article  PubMed  Google Scholar 

  161. Torres-Calleja J, González-Unzaga M, DeCelis-Carrillo R, Calzada-Sánchez L, Pedrón N. Effect of androgenic anabolic steroids on sperm quality and serum hormone levels in adult male bodybuilders. Life Sci. 2001;68(15):1769–74.

    Article  PubMed  CAS  Google Scholar 

  162. Moretti E, Collodel G, La Marca A, Piomboni P, Scapigliati G, Baccetti B. Structural sperm and aneuploidies studies in a case of spermatogenesis recovery after the use of androgenic anabolic steroids. J Assist Reprod Genet. 2007;24:195–8.

    Article  PubMed  CAS  Google Scholar 

  163. Turek PJ, Williams RH, Gilbaugh 3rd JH, Lipshultz LI. The reversibility of anabolic steroid-induced azoospermia. J Urol. 1995;153(5):1628–30.

    Article  PubMed  CAS  Google Scholar 

  164. Tanrikut C, McQuaid JW, Goldstein M. The impact of varicocele and varicocele repair on serum testosterone. Curr Opin Obstet Gynecol. 2011;23(4):227–31.

    Article  PubMed  Google Scholar 

  165. Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia. Fertil Steril. 2009;91(4 Suppl):1427–30.

    Article  PubMed  CAS  Google Scholar 

  166. Corona G, Rastrelli G, Vignozzi L, Maggi M. Emerging medication for the treatment of male hypogonadism. Expert Opin Emerg Drugs. 2012;17(2):239–59.

    Article  PubMed  CAS  Google Scholar 

  167. Gregoriou O, Bakas P, Grigoriadis C, Creatsa M, Hassiakos D, Creatsas G. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril. 2012;98(1):48–51.

    Article  PubMed  CAS  Google Scholar 

  168. Hsieh TC, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013;189(2):647–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter T. K. Chan M.D., C.M., M.Sc., F.R.C.S.(C)., F.A.C.S. .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Chan, P.T.K. (2013). Testosterone Replacement Therapy in Men: Effects on Fertility and Health. In: Schlegel, P., Fauser, B., Carrell, D., Racowsky, C. (eds) Biennial Review of Infertility. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7187-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-7187-5_4

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-7186-8

  • Online ISBN: 978-1-4614-7187-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics